If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, ...

Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...

Gilead Sciences will release its third-quarter earnings later this month, and analysts anticipate a single-digit bottom-line ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi for PBC patients who have difficulty with ...

Gilead Sciences Inc. (GILD) reached a notable milestone as its stock hit a 52-week high of $121.84, with InvestingPro data showing the company maintains a "GREAT" overall financial health score of ...

After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...

Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...